行情

ADMS

ADMS

Adamas Pharma
NASDAQ

实时行情|Nasdaq Last Sale

4.920
+0.060
+1.23%
交易中 11:53 09/24 EDT
开盘
4.810
昨收
4.860
最高
4.960
最低
4.768
成交量
4.58万
成交额
--
52周最高
9.15
52周最低
2.960
市值
2.24亿
市盈率(TTM)
-2.9157
分时
5日
1月
3月
1年
5年
Adamas 在即将召开的国际帕金森和运动障碍协会 (MDS) 大会上宣布 GOCOVRI 演讲
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parki...
Business Wire · 09/16 13:15
Adamas 宣布新的就业诱导补助金
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company's common stock. The restricted stock ...
Business Wire · 09/10 21:00
研究 Adamas Pharmaceuticals 的资本使用回报率
According to data from Benzinga Pro, during Q2, Adamas Pharmaceuticals's (NASDAQ:ADMS) reported sales totaled $21.97 million. Despite a 3.88% increase in earnings, the company posted a loss of $9.15 million.
Benzinga · 09/10 15:53
Adamas 将出席即将举行的 9 月投资者会议
EMERYVILLE, Calif., August 30, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will...
Business Wire · 08/30 20:11
Adamas Pharmaceuticals (ADMS) 报告第二季度亏损,收入预期滞后
Adamas (ADMS) delivered earnings and revenue surprises of 0.00% and -1.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/09 21:15
Adamas Pharmaceuticals Q2 每股收益 $(0.27) 超过 $(0.29) 估计,销售额 2200 万美元超过估计 2195 万美元
Adamas Pharmaceuticals (NASDAQ:ADMS) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 27.03 percent increase over losses of $(0.37) per share
Benzinga · 08/09 20:14
-- 盈利快报 (ADMS) ADAMAS PHARMACEUTICALS 报告第二季度收入为 2200 万美元,而 Street Est 为 2180 万美元
MT Newswires · 08/09 16:13
生物技术的未来一周(8 月 8 日至 14 日):Jazz Pharma FDA 的决定、收益泛滥和 IPO 成为焦点
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ADMS最新的财务预测,通过ADMS每股收益,每股净资产,每股现金流等数据分析Adamas Pharma近期的经营情况,然后做出明智的投资选择。
分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ADMS价格均价为8.79,最高价位14.00,最低价为3.000。
EPS
机构持股
总机构数: 123
机构持股: 3,277.04万
持股比例: 71.87%
总股本: 4,559.58万
类型机构数股数
增持
24
173.96万
建仓
9
292.87万
减持
14
141.90万
平仓
14
330.29万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.68%
制药与医学研究
-0.79%
高管信息
Chairman/Lead Director/Independent Director
David Mahoney
Chief Executive Officer/Director
Neil McFarlane
Chief Financial Officer/Chief Accounting Officer
Christopher Prentiss
Other
Adrian Quartel
Other
Vijay Shreedhar
Independent Director
Michael Bigham
Independent Director
Martha Demski
Independent Director
William Ericson
Independent Director
John MacPhee
Independent Director
Spyridon Papapetropoulos
Independent Director
Anna Richo
暂无数据
ADMS 简况
Adamas Pharmaceuticals Inc是一家商业阶段的制药公司。该公司从事药物发现、开发和商业化业务,为患者、护理人员和社会提供药物。该公司的产品组合GOCOVRI(金刚烷胺)缓释胶囊用于治疗帕金森氏病患者的运动障碍。OSMOLEX ER(金刚烷胺)缓释片用于治疗成人帕金森氏病和药物引起的锥体外系反应。用于治疗多发性硬化症(MSW)患者的步行障碍的ADS-5102正在开发中。其候选产品ADS-4101(拉科酰胺)释放胶囊正在开发中,用于治疗癫痫患者的部分发作性癫痫。其Namzaric(盐酸美金刚缓释和盐酸多奈哌齐)胶囊用于治疗阿尔茨海默氏症类型痴呆。

微牛提供Adamas Pharmaceuticals Inc(NASDAQ-ADMS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ADMS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ADMS股票基本功能。